Clinical trial • Phase III • Immunology
Clinical trial in Immune-related adverse events (CTCAE grade 2-4)
Phase III trial for Immune-related adverse events (CTCAE grade 2-4). 25 participants.
Overview
- Trial Therapeutic Area
- Immunology
- Trial Disease
- Immune-related adverse events (CTCAE grade 2-4)
- Trial Stage
- Phase III
Key dates
- Initial CTIS Submission Date
- 17-02-2026
- First CTIS Authorization Date
- 30-03-2026
Trial design
Phase III trial across 1 site in Denmark.
- Target Sample Size
- 25
Recruitment
- Planned Sample Size
- 25
- Recruitment Window Months
- 31
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 25
Denmark
- Earliest CTIS Part Ii Submission Date
- 20-03-2026
- Latest Decision Or Authorization Date
- 30-03-2026
- Processing Time Days
- 10
- Number Of Sites
- 1
- Number Of Participants
- 25
Sites
- Site Name
- Region Hovedstaden (Borgmester Ib Juuls Vej 1)
- Department Name
- Department of Oncology
- Principal Investigator Name
- Inge Marie Svane
- Principal Investigator Email
- inge.marie.svane@regionh.dk
- Contact Person Name
- Inge Marie Svane
- Contact Person Email
- inge.marie.svane@regionh.dk
- Number Of Participants
- 25
Sponsor
Primary sponsor
- Full Name
- Region Hovedstaden
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Denmark
Related trials
Other published trials that may interest you.
- BELIMUMAB for Antibody-mediated rejection (kidney transplant)|High HLA sensitization (transplant candidates)
- Belimumab for Systemic lupus erythematosus
- INEBILIZUMAB for Myasthenia gravis
- PREDNISONE for Granulomatosis with polyangiitis (Wegener's) | Microscopic polyangiitis | ANCA-associated vasculitis
- BIRCH POLLEN ALLERGOID GLUTARALDEHYDE MODIFIED for Allergic rhinitis due to birch pollen | Allergic rhinoconjunctivitis